NDAOPHTHALMICOINTMENT
Approved
Sep 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEODECADRON is a fixed-dose combination ophthalmic ointment containing dexamethasone sodium phosphate (a corticosteroid) and neomycin sulfate (an aminoglycoside antibiotic). It is used to treat inflammatory and infectious eye conditions, with the corticosteroid reducing inflammation and the antibiotic addressing bacterial infection. This combination addresses both the inflammatory and infectious components of ocular disease.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely operating in maintenance/optimization mode with minimal growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NEODECADRON presents limited career growth given its mature lifecycle, minimal linked job openings, and approaching LOE. Roles on this product focus on defensive sales, pricing strategy, and channel management rather than innovation or launch activities.
Brand ManagerField Sales Representative
Worked on NEODECADRON at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.